Therapeutic area intelligence for Myeloproliferative Neoplasms with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 1

Companies

JNJ-88549968 →

Assets

ASTX727 →

Pacritinib →

ruxolitinib →

Recent signals(3)

ClinicalAugust 13, 2026

Phase II Trial of ASTX727 with Iadademstat in Advanced Myeloproliferative Neoplasms

A phase II trial is evaluating the efficacy of ASTX727 combined with iadademstat versus ASTX727 alone in patients with advanced Philadelphia chromosome negative MPNs.

ClinicalAugust 12, 2026

Phase 1/2 Study of JNJ-88549968 in CALR-Mutated Myeloproliferative Neoplasms

A clinical trial is underway to evaluate the safety and dosing of JNJ-88549968 for CALR-mutated myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis.

ClinicalJuly 2, 2026

Phase I Trial of Pacritinib with Venetoclax and Azacitidine for Myeloproliferative Neoplasms

A Phase I trial is investigating the combination of pacritinib, venetoclax, and azacitidine for treating accelerated and blast phase myeloproliferative neoplasms.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.